Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucy Gilbert

Showing results (111-120 of 157) with videos related to

Pageof 16
Sort By:
Gynecologic Oncology|February 1, 2011
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancerKatherine M Bell-McGuinn, Carolyn M Matthews, Steffan N Ho, et al.
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
The Journal of Sexual Medicine|April 30, 2014
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
Ticks and Tick-Borne Diseases|March 27, 2026
Corrigendum to "Disentangling complex disease ecology networks: Using structural equation modelling to quantify the direct and indirect effects of deer on Lyme borreliosis hazard" [Ticks and Tick-borne Diseases 17 (2026) 102595]Sara L Gandy, Fernanda Sanchez-Rodríguez, William McLellan, et al.
Ticks and Tick-Borne Diseases|January 7, 2026
Disentangling complex disease ecology networks: Using structural equation modelling to quantify the direct and indirect effects of deer on Lyme borreliosis hazardSara L Gandy, Fernanda Sánchez-Rodríguez, William McLellan, et al.
Gynecologic Oncology|February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerDavid M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Menopause (New York, N.Y.)|May 14, 2009
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophyFernand Labrie, David Archer, Céline Bouchard, et al.
Menopause (New York, N.Y.)|May 9, 2009
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
Future Oncology (London, England)|June 29, 2023
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancerAna Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Cancer|January 16, 2025
Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysisYing L Liu, Cara A Mathews, Fiona Simpkins, et al.
Pageof 16

Showing results (111-120 of 157) with videos related to

Sort By:
Pageof 16
Gynecologic Oncology|February 1, 2011
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancerKatherine M Bell-McGuinn, Carolyn M Matthews, Steffan N Ho, et al.
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
The Journal of Sexual Medicine|April 30, 2014
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
Ticks and Tick-Borne Diseases|March 27, 2026
Corrigendum to "Disentangling complex disease ecology networks: Using structural equation modelling to quantify the direct and indirect effects of deer on Lyme borreliosis hazard" [Ticks and Tick-borne Diseases 17 (2026) 102595]Sara L Gandy, Fernanda Sanchez-Rodríguez, William McLellan, et al.
Ticks and Tick-Borne Diseases|January 7, 2026
Disentangling complex disease ecology networks: Using structural equation modelling to quantify the direct and indirect effects of deer on Lyme borreliosis hazardSara L Gandy, Fernanda Sánchez-Rodríguez, William McLellan, et al.
Gynecologic Oncology|February 22, 2020
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerDavid M O'Malley, Ursula A Matulonis, Michael J Birrer, et al.
Menopause (New York, N.Y.)|May 14, 2009
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophyFernand Labrie, David Archer, Céline Bouchard, et al.
Menopause (New York, N.Y.)|May 9, 2009
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal womenFernand Labrie, David Archer, Céline Bouchard, et al.
Future Oncology (London, England)|June 29, 2023
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancerAna Oaknin, Lucy Gilbert, Anna V Tinker, et al.
Cancer|January 16, 2025
Olaparib as treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysisYing L Liu, Cara A Mathews, Fiona Simpkins, et al.
Pageof 16